UP!
 |
|
|
Type
|
Public |
|---|---|
| Traded as | NASDAQ: TTNP |
| Industry | Pharmaceuticals |
| Headquarters | California |
|
Number of employees
|
14 (Dec 2016) |
| Website | www.titanpharm.com |
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA developing proprietary therapeutics primarily for the treatment of central nervous system ("CNS") disorders.
Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization.
| 2015-12-04 | Boost Price Target | Roth Capital | Buy | $6.50 to $7.25 |
| 2015-07-18 | Reiterated Rating | Roth Capital | Buy | $1.25 to $1.50 |
| 2015-06-12 | Reiterated Rating | Roth Capital | Buy | $1.25 |
| 2015-01-20 | Initiated Coverage | Roth Capital | Buy | $1.25 |
| 1970-01-01 |
| 2015-12-04 | Boost Price Target | Roth Capital | Buy | $6.50 to $7.25 |
| 2015-07-18 | Reiterated Rating | Roth Capital | Buy | $1.25 to $1.50 |
| 2015-06-12 | Reiterated Rating | Roth Capital | Buy | $1.25 |
| 2015-01-20 | Initiated Coverage | Roth Capital | Buy | $1.25 |
| 1970-01-01 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In TTNP 0 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|
UM